8-Azabicyclo[3.2.1]octan-3-ol,8-methyl-methanesulfonate(ester),exo-

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: 8-Azabicyclo[3.2.1]octan-3-ol,8-methyl-methanesulfonate(ester),exo-
• 英文别名: 8-azabicyclo[3.2.1]octan-3-yl methanesulfonate
• 化学式: C₈H₁₅NO₃S
• 分子量: 205.28
• InChiKey: URNUWLMICVUWRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  63.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Receptor-Type Kinase Modulators and Methods of Use
  申请人：Rice Kenneth D.

  公开号：US20160129032A1

  公开（公告）日：2016-05-12

  The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.

  本发明提供了用于调节受体激酶活性的化合物，特别是ephrin和EGFR，并利用这些化合物及其药物组合物治疗由受体激酶活性介导的疾病的方法。由受体激酶活性介导的疾病包括但不限于部分表现为细胞增殖异常水平（即肿瘤生长）、程序性细胞死亡（凋亡）、细胞迁移和侵袭以及与肿瘤生长相关的血管生成的疾病。本发明的化合物包括“谱选择性”激酶调节剂，这些化合物抑制、调节和/或调节跨受体型酪氨酸激酶亚家族的信号传导，包括ephrin和EGFR。
• Receptor-type kinase modulators and methods of use
  申请人：Rice Kenneth D.

  公开号：US20090318373A1

  公开（公告）日：2009-12-24

  The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.

  本发明提供了用于调节受体激酶活性的化合物，特别是调节ephrin和EGFR的化合物，以及利用这些化合物和其制剂治疗由受体激酶活性介导的疾病的方法。由受体激酶活性介导的疾病包括但不限于部分以细胞增殖水平异常（即肿瘤生长）、程序性细胞死亡（凋亡）、细胞迁移和侵袭以及与肿瘤生长相关的血管生成为特征的疾病。本发明的化合物包括“谱选择性”激酶调节剂，这些化合物抑制、调节和/或调节受体型酪氨酸激酶亚家族之间的信号转导，包括ephrin和EGFR。
• Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof
  申请人：Symphony Evolution, Inc.

  公开号：US10266518B2

  公开（公告）日：2019-04-23

  The present invention provides compounds of Formula I, for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.

  本发明提供了式 I 的化合物、 用于调节受体激酶活性，特别是表皮生长因子受体和表皮生长因子受体，以及利用其化合物和药物组合物治疗由受体激酶活性介导的疾病的方法。由受体激酶活性介导的疾病包括但不限于部分以异常水平的细胞增殖（即肿瘤生长）、程序性细胞死亡（凋亡）、细胞迁移和侵袭以及与肿瘤生长相关的血管生成为特征的疾病。本发明的化合物包括 "谱系选择性 "激酶调节剂，即抑制、调节和/或调节包括表皮生长因子受体和表皮生长因子受体在内的受体型酪氨酸激酶亚家族信号转导的化合物。
• RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE
  申请人：Symphony Evolution, Inc.

  公开号：EP1521747B1

  公开（公告）日：2018-09-05
• US7576074B2
  申请人：——

  公开号：US7576074B2

  公开（公告）日：2009-08-18